Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 73Lung Neoplasms 32Triple Negative Breast Neoplasms 23Breast Neoplasms 19Small Cell Lung Carcinoma 15Ovarian Neoplasms 15Endometrial Neoplasms 14Squamous Cell Carcinoma of Head and Neck 13Parkinson Disease 4, Autosomal Dominant Lewy Body 12Neoplasms 12Fallopian Tube Neoplasms 10Neoplasm Metastasis 9Colorectal Neoplasms 6Urinary Bladder Neoplasms 5Carcinoma 5Adenocarcinoma of Lung 5Esophageal Neoplasms 4Uterine Cervical Neoplasms 3Pathologic Complete Response 3Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Mesothelioma 3Melanoma 3Lung Diseases 3Head and Neck Neoplasms 3Esophageal Squamous Cell Carcinoma 3Central Nervous System Neoplasms 3Uterine Neoplasms 2Thoracic Neoplasms 2Sarcoma 2

Interventions

Gemcitabine 8Cisplatin 8durvalumab 4Oxaliplatin 3Irinotecan 3Folfox protocol 3Bevacizumab 3zanidatamab 2pembrolizumab 2Fluorouracil 2Capecitabine 2tremelimumab 1trastuzumab deruxtecan 1toripalimab 1poly ICLC 1niraparib 1neratinib 1ivosidenib 1futibatinib 1fludarabine 1envafolimab 1encorafenib 1brigimadlin 1binimetinib 1apatinib 1Trastuzumab 1Self Expandable Metallic Stents 1Psilocybin 1Peptides 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × Carboplatin × 30 days × Clear all
NCT04956640 2026-05-29

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Eli Lilly and Company

Phase 1/2 Active not recruiting
540 enrolled
GastrointestinalGynecologicThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡